Ovarian and Endometrial Endometrioid Carcinoma Following the Use of a Biologic IL-17 Inhibitor
Evidence suggests that IL-17, a pro-inflammatory cytokine, suppresses tumor carcinogenesis; therefore, the use of IL-17 inhibitors accelerates carcinoma growth. We present a case of a perimenopausal female who was diagnosed with synchronous primary ovarian and endometrial endometrioid carcinoma foll...
Gespeichert in:
| Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2023-07, Vol.15 (7) |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | |
| container_title | Curēus (Palo Alto, CA) |
| container_volume | 15 |
| creator | Babcock, Luke Singer, Samantha R Carbiener, Pamela |
| description | Evidence suggests that IL-17, a pro-inflammatory cytokine, suppresses tumor carcinogenesis; therefore, the use of IL-17 inhibitors accelerates carcinoma growth. We present a case of a perimenopausal female who was diagnosed with synchronous primary ovarian and endometrial endometrioid carcinoma following the use of secukinumab, a monoclonal antibody against IL-17. After eight months of secukinumab, she developed progressive vaginal bleeding, left upper quadrant pain, and abdominal distention. CT imaging displayed a large abdominal mass, and biopsies produced the diagnosis. It is proposed that by inhibiting IL-17, carcinogenesis was expedited. This case highlights a relationship between secukinumab and accelerated carcinogenesis. Consequently, due to the incidence of endometrial carcinoma and the morbidity rate of ovarian carcinoma, individuals taking IL-17 inhibitors may need prophylactic screening and close monitoring. |
| doi_str_mv | 10.7759/cureus.42481 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10452048</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2859482070</sourcerecordid><originalsourceid>FETCH-LOGICAL-c244t-292400d66588794cb1940650a9f5e8805dc5d9fb6c1850073dfdba58415761a83</originalsourceid><addsrcrecordid>eNpVkU9PAjEQxRujiUS5-QGaeHVxWtpt92SUgJKQcJGrTbftQsnSYncX47cXhPjnNG8yL28m80PohsBACF7cmy65rhkwyiQ5Qz1KcplJItn5H32J-k2zBgACgoKAHnqb73TyOmAdLB4HGzeu3ff1r47e4pFOxoe40XgS6zp--LDE7crhReNwrLDGTz7WcekNns4yIvA0rHzp25iu0UWl68b1T_UKLSbj19FLNps_T0ePs8xQxtqMFpQB2DznUoqCmZIUDHIOuqi4kxK4NdwWVZkbIjmAGNrKlppLRrjIiZbDK_RwzN125cZZ40KbdK22yW90-lRRe_V_EvxKLeNOEWCcAjsk3J4SUnzvXNOqdexS2B-tqOQFk4d_7V13R5dJsWmSq35WEFAHDOqIQX1jGH4Bytd7lQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2859482070</pqid></control><display><type>article</type><title>Ovarian and Endometrial Endometrioid Carcinoma Following the Use of a Biologic IL-17 Inhibitor</title><source>Open Access: PubMed Central</source><source>PubMed Central Open Access</source><creator>Babcock, Luke ; Singer, Samantha R ; Carbiener, Pamela</creator><creatorcontrib>Babcock, Luke ; Singer, Samantha R ; Carbiener, Pamela</creatorcontrib><description>Evidence suggests that IL-17, a pro-inflammatory cytokine, suppresses tumor carcinogenesis; therefore, the use of IL-17 inhibitors accelerates carcinoma growth. We present a case of a perimenopausal female who was diagnosed with synchronous primary ovarian and endometrial endometrioid carcinoma following the use of secukinumab, a monoclonal antibody against IL-17. After eight months of secukinumab, she developed progressive vaginal bleeding, left upper quadrant pain, and abdominal distention. CT imaging displayed a large abdominal mass, and biopsies produced the diagnosis. It is proposed that by inhibiting IL-17, carcinogenesis was expedited. This case highlights a relationship between secukinumab and accelerated carcinogenesis. Consequently, due to the incidence of endometrial carcinoma and the morbidity rate of ovarian carcinoma, individuals taking IL-17 inhibitors may need prophylactic screening and close monitoring.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.42481</identifier><language>eng</language><publisher>Palo Alto: Cureus Inc</publisher><subject>Abdomen ; Cancer therapies ; Case reports ; Cohort analysis ; Cytokines ; Endometrial cancer ; Family medical history ; Gynecology ; Medical imaging ; Monoclonal antibodies ; Obstetrics ; Obstetrics/Gynecology ; Oncology ; Ovarian cancer ; Patients ; Preventive Medicine ; Psoriasis ; Risk factors ; Skin cancer ; Tomography ; Tumor necrosis factor-TNF ; Tumors ; Uterus ; Vagina</subject><ispartof>Curēus (Palo Alto, CA), 2023-07, Vol.15 (7)</ispartof><rights>Copyright © 2023, Babcock et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2023, Babcock et al. 2023 Babcock et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c244t-292400d66588794cb1940650a9f5e8805dc5d9fb6c1850073dfdba58415761a83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452048/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452048/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Babcock, Luke</creatorcontrib><creatorcontrib>Singer, Samantha R</creatorcontrib><creatorcontrib>Carbiener, Pamela</creatorcontrib><title>Ovarian and Endometrial Endometrioid Carcinoma Following the Use of a Biologic IL-17 Inhibitor</title><title>Curēus (Palo Alto, CA)</title><description>Evidence suggests that IL-17, a pro-inflammatory cytokine, suppresses tumor carcinogenesis; therefore, the use of IL-17 inhibitors accelerates carcinoma growth. We present a case of a perimenopausal female who was diagnosed with synchronous primary ovarian and endometrial endometrioid carcinoma following the use of secukinumab, a monoclonal antibody against IL-17. After eight months of secukinumab, she developed progressive vaginal bleeding, left upper quadrant pain, and abdominal distention. CT imaging displayed a large abdominal mass, and biopsies produced the diagnosis. It is proposed that by inhibiting IL-17, carcinogenesis was expedited. This case highlights a relationship between secukinumab and accelerated carcinogenesis. Consequently, due to the incidence of endometrial carcinoma and the morbidity rate of ovarian carcinoma, individuals taking IL-17 inhibitors may need prophylactic screening and close monitoring.</description><subject>Abdomen</subject><subject>Cancer therapies</subject><subject>Case reports</subject><subject>Cohort analysis</subject><subject>Cytokines</subject><subject>Endometrial cancer</subject><subject>Family medical history</subject><subject>Gynecology</subject><subject>Medical imaging</subject><subject>Monoclonal antibodies</subject><subject>Obstetrics</subject><subject>Obstetrics/Gynecology</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Patients</subject><subject>Preventive Medicine</subject><subject>Psoriasis</subject><subject>Risk factors</subject><subject>Skin cancer</subject><subject>Tomography</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumors</subject><subject>Uterus</subject><subject>Vagina</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpVkU9PAjEQxRujiUS5-QGaeHVxWtpt92SUgJKQcJGrTbftQsnSYncX47cXhPjnNG8yL28m80PohsBACF7cmy65rhkwyiQ5Qz1KcplJItn5H32J-k2zBgACgoKAHnqb73TyOmAdLB4HGzeu3ff1r47e4pFOxoe40XgS6zp--LDE7crhReNwrLDGTz7WcekNns4yIvA0rHzp25iu0UWl68b1T_UKLSbj19FLNps_T0ePs8xQxtqMFpQB2DznUoqCmZIUDHIOuqi4kxK4NdwWVZkbIjmAGNrKlppLRrjIiZbDK_RwzN125cZZ40KbdK22yW90-lRRe_V_EvxKLeNOEWCcAjsk3J4SUnzvXNOqdexS2B-tqOQFk4d_7V13R5dJsWmSq35WEFAHDOqIQX1jGH4Bytd7lQ</recordid><startdate>20230726</startdate><enddate>20230726</enddate><creator>Babcock, Luke</creator><creator>Singer, Samantha R</creator><creator>Carbiener, Pamela</creator><general>Cureus Inc</general><general>Cureus</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20230726</creationdate><title>Ovarian and Endometrial Endometrioid Carcinoma Following the Use of a Biologic IL-17 Inhibitor</title><author>Babcock, Luke ; Singer, Samantha R ; Carbiener, Pamela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c244t-292400d66588794cb1940650a9f5e8805dc5d9fb6c1850073dfdba58415761a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Abdomen</topic><topic>Cancer therapies</topic><topic>Case reports</topic><topic>Cohort analysis</topic><topic>Cytokines</topic><topic>Endometrial cancer</topic><topic>Family medical history</topic><topic>Gynecology</topic><topic>Medical imaging</topic><topic>Monoclonal antibodies</topic><topic>Obstetrics</topic><topic>Obstetrics/Gynecology</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Patients</topic><topic>Preventive Medicine</topic><topic>Psoriasis</topic><topic>Risk factors</topic><topic>Skin cancer</topic><topic>Tomography</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumors</topic><topic>Uterus</topic><topic>Vagina</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Babcock, Luke</creatorcontrib><creatorcontrib>Singer, Samantha R</creatorcontrib><creatorcontrib>Carbiener, Pamela</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Babcock, Luke</au><au>Singer, Samantha R</au><au>Carbiener, Pamela</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ovarian and Endometrial Endometrioid Carcinoma Following the Use of a Biologic IL-17 Inhibitor</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><date>2023-07-26</date><risdate>2023</risdate><volume>15</volume><issue>7</issue><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Evidence suggests that IL-17, a pro-inflammatory cytokine, suppresses tumor carcinogenesis; therefore, the use of IL-17 inhibitors accelerates carcinoma growth. We present a case of a perimenopausal female who was diagnosed with synchronous primary ovarian and endometrial endometrioid carcinoma following the use of secukinumab, a monoclonal antibody against IL-17. After eight months of secukinumab, she developed progressive vaginal bleeding, left upper quadrant pain, and abdominal distention. CT imaging displayed a large abdominal mass, and biopsies produced the diagnosis. It is proposed that by inhibiting IL-17, carcinogenesis was expedited. This case highlights a relationship between secukinumab and accelerated carcinogenesis. Consequently, due to the incidence of endometrial carcinoma and the morbidity rate of ovarian carcinoma, individuals taking IL-17 inhibitors may need prophylactic screening and close monitoring.</abstract><cop>Palo Alto</cop><pub>Cureus Inc</pub><doi>10.7759/cureus.42481</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-8184 |
| ispartof | Curēus (Palo Alto, CA), 2023-07, Vol.15 (7) |
| issn | 2168-8184 2168-8184 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10452048 |
| source | Open Access: PubMed Central; PubMed Central Open Access |
| subjects | Abdomen Cancer therapies Case reports Cohort analysis Cytokines Endometrial cancer Family medical history Gynecology Medical imaging Monoclonal antibodies Obstetrics Obstetrics/Gynecology Oncology Ovarian cancer Patients Preventive Medicine Psoriasis Risk factors Skin cancer Tomography Tumor necrosis factor-TNF Tumors Uterus Vagina |
| title | Ovarian and Endometrial Endometrioid Carcinoma Following the Use of a Biologic IL-17 Inhibitor |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A23%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ovarian%20and%20Endometrial%20Endometrioid%20Carcinoma%20Following%20the%20Use%20of%20a%20Biologic%20IL-17%20Inhibitor&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Babcock,%20Luke&rft.date=2023-07-26&rft.volume=15&rft.issue=7&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.42481&rft_dat=%3Cproquest_pubme%3E2859482070%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2859482070&rft_id=info:pmid/&rfr_iscdi=true |